Linezolid Sandoz Ltd

Linezolid, the active ingredient in Linezolid Sandoz Ltd, is an oxazolidinone antibiotic presented as an intravenous solution for intravenous use. It treats infections caused by Gram‑positive bacteria, including MRSA and VRE, in adult patients.

GNH USA supplies Linezolid Sandoz Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibiotic used to treat serious Gram‑positive bacterial infections.

- Complicated skin and soft‑tissue infections: reduces bacterial load and promotes healing. - Community‑acquired pneumonia: improves clinical outcomes in adult patients. - Hospital‑acquired pneumonia: effective against resistant Gram‑positive pathogens.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limited. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Rash: mild skin erythema. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Myelosuppression: decreased blood cell counts, requiring monitoring. - Peripheral neuropathy: sensory changes, potentially irreversible. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Severe hypotension: sudden drop in blood pressure. - Optic neuritis: visual disturbances, may be permanent.

When prescribing Linezolid, clinicians should consider several safety measures.

- Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution in severe liver disease. - Concomitant serotonergic drugs: avoid due to serotonin syndrome risk. - Hematologic monitoring: check complete blood count regularly. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Linezolid interacts with several medication classes that may require avoidance or close monitoring.

Major Interactions (Avoid): - SSRIs, SNRIs, MAO inhibitors: increased risk of serotonin syndrome. - Tramadol or meperidine: heightened serotonin toxicity. - Rifampin: reduces linezolid plasma concentrations, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Phenytoin: enzyme induction may lower linezolid levels. - NSAIDs: potential additive effect on bleeding risk.